All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib. - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Oncotarget Année : 2012

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib.

Résumé

The advent of tyrosine kinase inhibitor (TKI) therapy has considerably improved the survival of patients suffering chronic myelogenous leukemia (CML). Indeed, inhibition of BCR-ABL by imatinib, dasatinib or nilotinib triggers durable responses in most patients suffering from this disease. Moreover, resistance to imatinib due to kinase domain mutations can be generally circumvented using dasatinib or nilotinib, but the multi-resistant T315I mutation that is insensitive to these TKIs, remains to date a major clinical problem. In this line, ponatinib (AP24534) has emerged as a promising therapeutic option in patients with all kinds of BCR-ABL mutations, especially the T315I one. However and surprisingly, the effect of ponatinib has not been extensively studied on imatinib-resistant CML cell lines. Therefore, in the present study, we used several CML cell lines with different mechanisms of resistance to TKI to evaluate the effect of ponatinib on cell viability, apoptosis and signaling. Our results show that ponatinib is highly effective on both sensitive and resistant CML cell lines, whatever the mode of resistance and also on BaF3 murine B cells carrying native BCR-ABL or T315I mutation. We conclude that ponatinib could be effectively used for all types of TKI-resistant patients.
Fichier non déposé

Dates et versions

hal-00771186 , version 1 (08-01-2013)

Identifiants

  • HAL Id : hal-00771186 , version 1
  • PUBMED : 23238683

Citer

Ophélie Cassuto, Maeva Dufies, Arnaud Jacquel, Guillaume Robert, Clémence Ginet, et al.. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib.. Oncotarget, 2012, epub ahead of print. ⟨hal-00771186⟩
162 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More